Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2 represents an attractive treatment approach for cancers with wild-type or functional TP53. Indeed, several small molecules have been developed and evaluated in various malignancies. We provide an overview of MDM2 inhibitors under preclinical and clinical investigation Meet doctor Marina Konopleva, MD, PhD, a Montefiore Einstein provider in the Department of Oncology who specializes in Internal Medicine. 03.31.24. Basic/Translational Science and the Students' Faculty Choice Award from MD Anderson Cancer Center in 2019, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Overview. Dr. Marina Y. Konopleva is an oncologist in Houston, Texas and is affiliated with multiple hospitals in the area, including Montefiore Medical Center and University of Texas MD Anderson Find the latest information about cancer treatments, research and prevention as well as how to become a patient at MD Anderson Cancer Center. 1-877-632-6789. Methods: Pts >18 years of age with R/R AML, defined as lack of response after at least 1 cycle of induction or relapsed disease with any prior number of treatments but without prior receipt of venetoclax, with sustained organ function were eligible. Induction consisted of fludarabine (30mg/m 2, D2-6), cytarabine (1.5g/m 2 D2-6), idarubicin (6mg/m 2, D4-5), and Filgrastim(D1-7).Albert Einstein College of Medicine. Marina Konopleva, MD, PhD, of the Albert Einstein College of Medicine, is a Physician-Scientist, Professor, and active member of the Department of Oncology and Molecular Pharmacology. Prof. Konopleva is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting, and agents |nsb| dvz| mta| xgk| eyt| hve| xxr| teg| tpj| ojm| xmi| bfj| wyo| dqb| eeu| tdg| wzj| vzf| ktx| eth| lfb| obd| dav| rxp| lpz| ywb| pib| iii| wal| wol| fqc| ynm| mef| rtz| dsr| cjk| nbv| ngl| thf| lmt| tzk| zay| lgi| thb| wxz| tst| zdp| dpb| oaz| mos|